{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:20:51Z","timestamp":1787656851919,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05043-1","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:29:32Z","timestamp":1770359372000},"page":"3795-3811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of budesonide for the treatment of IgA nephropathy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"given":"Rayyan","family":"Nabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ansab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza Bin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najaf Ahmed","family":"Rajpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahat Ul Ain Munir","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka Keshav","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owais","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzala Ahmed","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabeer","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"5","key":"5043_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I (2018) Epidemiology of IgA nephropathy: a global perspective. Sem Nephrol 38(5):435\u2013442","journal-title":"Sem Nephrol"},{"issue":"2","key":"5043_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00005792-199403000-00002","volume":"73","author":"Ls Ibels","year":"1994","unstructured":"Ibels Ls, Gy\u00f6ry AZ (1994) IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore) 73(2):79","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"5043_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, A. Inker L, Floege J, Perkovic V, Boyer-Suavet S et al (2019) Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol CJASN 14(3):469\u2013481","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"5043_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100759","author":"ME Bensink","year":"2024","unstructured":"Bensink ME, Goldschmidt D, Zhou ZY, Wang K, Lieblich R, Bunke MC (2024) Kidney failure attributed to immunoglobulin a nephropathy: a USRDS retrospective cohort study of epidemiology, treatment modalities, and economic burden. Kidney Med. https:\/\/doi.org\/10.1016\/j.xkme.2023.100759","journal-title":"Kidney Med."},{"issue":"1","key":"5043_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40620-015-0248-3","volume":"29","author":"C Pozzi","year":"2016","unstructured":"Pozzi C (2016) Treatment of IgA nephropathy. J Nephrol 29(1):21\u201325","journal-title":"J Nephrol"},{"issue":"4","key":"5043_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Bernier-Jean A, Barratt J, Rovin B (2025) Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int 107(4):640\u2013651","journal-title":"Kidney Int"},{"key":"5043_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1242241\/full","author":"Y Dong","year":"2023","unstructured":"Dong Y, Shi S, Liu L, Zhou X, Lv J, Zhang H (2023) Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy. Front Med. https:\/\/doi.org\/10.3389\/fmed.2023.1242241\/full","journal-title":"Front Med"},{"key":"5043_CR8","unstructured":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases\u2014Kidney International [Internet]. [cited 2025 Oct 10]. Available from: https:\/\/www.kidney-international.org\/article\/S0085-2538(21)00553-6\/fulltext"},{"issue":"9156","key":"5043_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco P, Fogazzi G, Andrulli S, Altieri P, Ponticelli C et al (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. The Lancet 353(9156):883\u2013887","journal-title":"The Lancet"},{"issue":"4","key":"5043_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MNH.0000000000000336","volume":"26","author":"S Barbour","year":"2017","unstructured":"Barbour S, Feehally J (2017) An update on the treatment of IgA nephropathy. Curr Opin Nephrol Hypertens 26(4):319","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"19","key":"5043_CR11","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H et al (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy. JAMA 327(19):1888\u20131898","journal-title":"JAMA"},{"issue":"5","key":"5043_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000543271","volume":"149","author":"E Mitsopoulos","year":"2024","unstructured":"Mitsopoulos E, Pateinakis P, Keskinis C, Papadopoulou D (2024) A case of complete remission of glucocorticoid-dependent nephrotic syndrome after targeted-release formulation of budesonide treatment in a patient with mild mesangial proliferative IgA nephropathy. Nephron 149(5):283\u2013287","journal-title":"Nephron"},{"issue":"2","key":"5043_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J et al (2023) Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 103(2):391\u2013402","journal-title":"Kidney Int"},{"issue":"5","key":"5043_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/diagnostics14050512","volume":"14","author":"C Keskinis","year":"2024","unstructured":"Keskinis C, Moysidou E, Christodoulou M, Pateinakis P, Stangou M (2024) Diagnosing and treating IgAN: steroids, budesonide, or maybe both? Diagnostics 14(5):512","journal-title":"Diagnostics"},{"issue":"5","key":"5043_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0091-6749(98)70019-3","volume":"102","author":"G Shapiro","year":"1998","unstructured":"Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA (1998) Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid\u2013dependent, persistent asthma. J Allergy Clin Immunol 102(5):789\u2013796","journal-title":"J Allergy Clin Immunol"},{"key":"5043_CR16","doi-asserted-by":"publisher","unstructured":"Budesonide (Entocort\u00ae EC Capsules)|Drugs [Internet]. [cited 2025 Oct 10]. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.2165\/00003495-200262150-00015","DOI":"10.2165\/00003495-200262150-00015"},{"issue":"3","key":"5043_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","volume":"63","author":"SPL Travis","year":"2014","unstructured":"Travis SPL, Danese S, Kupcinskas L, Alexeeva O, D\u2019Haens G, Gibson PR et al (2014) Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 63(3):433\u2013441","journal-title":"Gut"},{"issue":"372","key":"5043_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ 29(372):n71","journal-title":"The BMJ"},{"issue":"366","key":"5043_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 28(366):l4898","journal-title":"BMJ"},{"issue":"355","key":"5043_CR20","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"12","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. The BMJ 12(355):i4919","journal-title":"The BMJ"},{"key":"5043_CR21","unstructured":"The Handbook of Research Synthesis and Meta-Analysis, Second Edition|Russell Sage Foundation [Internet]. [cited 2025 Oct 10]. Available from: https:\/\/www.russellsage.org\/publications\/book\/handbook-research-synthesis-and-meta-analysis-second-edition"},{"issue":"18","key":"5043_CR22","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/sim.1221","volume":"21","author":"B Baujat","year":"2002","unstructured":"Baujat B, Mah\u00e9 C, Pignon JP, Hill C (2002) A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med 21(18):2641\u20132652","journal-title":"Stat Med"},{"issue":"3","key":"5043_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/00401706.1988.10488400","volume":"30","author":"RF Galbraith","year":"1988","unstructured":"Galbraith RF (1988) Graphical display of estimates having differing standard errors. Technometrics 30(3):271\u2013281","journal-title":"Technometrics"},{"issue":"4","key":"5043_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR (2018) A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc 16(4):195","journal-title":"Int J Evid Based Healthc"},{"issue":"26","key":"5043_CR25","doi-asserted-by":"publisher","first-page":"e21000","DOI":"10.1097\/MD.0000000000021000","volume":"99","author":"G Ismail","year":"2020","unstructured":"Ismail G, Obri\u015fc\u0103 B, Jurubi\u0163\u0103 R, Andronesi A, Sorohan B, Vornicu A et al (2020) Budesonide versus systemic corticosteroids in IgA nephropathy: a retrospective, propensity-matched comparison. Medicine (Baltimore) 99(26):e21000","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"5043_CR26","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","volume":"26","author":"HK Smerud","year":"2011","unstructured":"Smerud HK, B\u00e1r\u00e1ny P, Lindstr\u00f6m K, Fernstr\u00f6m A, Sandell A, P\u00e5hlsson P et al (2011) New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 26(10):3237\u20133242","journal-title":"Nephrol Dial Transplant"},{"issue":"35","key":"5043_CR27","doi-asserted-by":"publisher","first-page":"10693","DOI":"10.3389\/ti.2022.10693","volume":"14","author":"M Lopez-Martinez","year":"2022","unstructured":"Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A et al (2022) Enteric budesonide in transplant and native IgA nephropathy: real-world clinical practice. Transpl Int 14(35):10693","journal-title":"Transpl Int"},{"issue":"10084","key":"5043_CR28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW et al (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. The Lancet 389(10084):2117\u20132127","journal-title":"The Lancet"},{"issue":"10405","key":"5043_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H et al (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402(10405):859\u2013870","journal-title":"Lancet"},{"issue":"13","key":"5043_CR30","doi-asserted-by":"publisher","first-page":"20119","DOI":"10.1038\/s41598-023-47393-1","volume":"17","author":"B Obri\u0219c\u0103","year":"2023","unstructured":"Obri\u0219c\u0103 B, Vornicu A, Mocanu V, Dimofte G, Andronesi A, Bobeic\u0103 R et al (2023) An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression. Sci Rep 17(13):20119","journal-title":"Sci Rep"},{"issue":"6","key":"5043_CR31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4103\/1319-2442.390255","volume":"33","author":"U Lingaraj","year":"2022","unstructured":"Lingaraj U, Mallapur S, Viswanathan A, Vankalakunti M (2022) Clinical response to intestine-targeted steroid therapy in biopsy-proven immunoglobulin A nephropathy. Saudi J Kidney Dis Transpl 33(6):755","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"1","key":"5043_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/ckj\/sfae364","volume":"18","author":"C Keskinis","year":"2025","unstructured":"Keskinis C, Moysidou E, Kapsia E, Vaios V, Bintas C, Trivyza M et al (2025) Factors influencing early response of IgA nephropathy following targeted-release budesonide (TRB) treatment: preliminary results from a multicenter study. Clin Kidney J 18(1):364","journal-title":"Clin Kidney J"},{"issue":"5","key":"5043_CR33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/medicina61050807","volume":"61","author":"C Keskinis","year":"2025","unstructured":"Keskinis C, Moysidou E, Stai S, Christodoulou M, Lioulios G, Vamvakas SS et al (2025) Prognostic value of urinary biomarkers in proteinuria progression in IgA nephropathy patients treated with budesonide. Medicina (Mex) 61(5):807","journal-title":"Medicina (Mex)"},{"issue":"2","key":"5043_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","volume":"361","author":"A Rajasekaran","year":"2021","unstructured":"Rajasekaran A, Julian BA, Rizk DV (2021) IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci 361(2):176\u2013194","journal-title":"Am J Med Sci"},{"issue":"4","key":"5043_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/ndt\/gfx189","volume":"33","author":"MM O\u2019Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC (2018) Glomerular disease frequencies by race, sex and region: results from the international kidney biopsy survey. Nephrol Dial Transplant 33(4):661\u2013669","journal-title":"Nephrol Dial Transplant"},{"issue":"172","key":"5043_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clim.2016.07.011","volume":"1","author":"J Mestecky","year":"2016","unstructured":"Mestecky J, Novak J, Moldoveanu Z, Raska M (2016) IgA nephropathy enigma. Clin Immunol 1(172):72\u201377","journal-title":"Clin Immunol"},{"issue":"2","key":"5043_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/CJN.04660513","volume":"9","author":"JM Ambruzs","year":"2014","unstructured":"Ambruzs JM, Walker PD, Larsen CP (2014) The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol 9(2):265","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"5043_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01426.x","volume":"17","author":"S Edsb\u00e4cker","year":"2003","unstructured":"Edsb\u00e4cker S, Bengtsson B, Larsson P, Lundin P, Nilsson \u00c5, Ulmius J et al (2003) A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 17(4):525\u2013536","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"5043_CR39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/17425247.2.1.159","volume":"2","author":"P Watts","year":"2005","unstructured":"Watts P, Smith A (2005) TARGIT\u2122 technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract. Expert Opin Drug Deliv 2(1):159\u2013167","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"5043_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1586\/eci.11.34","volume":"7","author":"J Silverman","year":"2011","unstructured":"Silverman J, Otley A (2011) Budesonide in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 7(4):419\u2013428","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"5043_CR41","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/jgh.14151","volume":"33","author":"S Miehlke","year":"2018","unstructured":"Miehlke S, de Acosta MB, Bouma G, Carpio D, Magro F, Moreels T et al (2018) Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. J Gastroenterol Hepatol 33(9):1574\u20131581","journal-title":"J Gastroenterol Hepatol"},{"key":"5043_CR42","unstructured":"Research C for DE and. FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. FDA [Internet]. 2024 Aug 9 [cited 2025 Oct 10]; Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease"},{"issue":"6","key":"5043_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA et al (2023) Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 18(6):727","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"5043_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","volume":"24","author":"G D\u2019Amico","year":"2004","unstructured":"D\u2019Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24(3):179\u2013196","journal-title":"Semin Nephrol"},{"issue":"3","key":"5043_CR45","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","volume":"68","author":"LA Inker","year":"2016","unstructured":"Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP et al (2016) Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis 68(3):392\u2013401","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"5043_CR46","doi-asserted-by":"publisher","first-page":"2195012","DOI":"10.1080\/0886022X.2023.2195012","volume":"45","author":"ZY Tian","year":"2023","unstructured":"Tian ZY, Li Z, Chu L, Liu Y, He JR, Xin Y et al (2023) Iron metabolism and chronic inflammation in IgA nephropathy. Ren Fail 45(1):2195012","journal-title":"Ren Fail"},{"issue":"6","key":"5043_CR47","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s10157-018-1555-5","volume":"22","author":"Y Zou","year":"2018","unstructured":"Zou Y, Yang M, Du X (2018) New insight into the management of IgA nephropathy. Clin Exp Nephrol 22(6):1442\u20131443","journal-title":"Clin Exp Nephrol"},{"key":"5043_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2025.101078","author":"ZG Ghozloujeh","year":"2025","unstructured":"Ghozloujeh ZG, Selvaskandan H, Wiegley N, Lerma E, Gaytan J, Garcia-Rivera A et al (2025) IgA nephropathy: an overview of the clinical trials. Kidney Med. https:\/\/doi.org\/10.1016\/j.xkme.2025.101078","journal-title":"Kidney Med"},{"issue":"9","key":"5043_CR49","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/ndt\/gfaf039","volume":"40","author":"C Keskinis","year":"2025","unstructured":"Keskinis C, Pateinakis P, Stangou M (2025) Re-biopsy may guide novel immunosuppressive therapy in long-standing IgA nephropathy. Nephrol Dial Transplant 40(9):1639\u20131642","journal-title":"Nephrol Dial Transplant"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05043-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05043-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05043-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:40:24Z","timestamp":1787654424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05043-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5043"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05043-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval is deemed unnecessary according to national regulations, as our study did not involve any human\/animal test subject (\n                      \n                      ). The need for consent to participate is deemed unnecessary according to national regulations as our study did not involve any human\/animal test subject (\n                      \n                      ), and the data used in this study is de-identified and publicly available; thus, no institutional review board approval was required. We ensured adherence to the ethical principles outlined in the Declaration of Helsinki. This has been clearly stated under the Declarations section in the manuscript.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}